NovoCure Ltd
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(a) None.
(b)Securities Trading Plans of Executive Officers and Directors
Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables prearranged transactions in securities in a manner that avoids concerns about initiating transactions at a future date while possibly in possession of material nonpublic information. Our Insider Trading Policy permits our executive officers and directors to enter into trading plans designed to comply with Rule 10b5-1.
During the three-month period ending December 31, 2024, we didnot adopt orterminate any contract, instruction or written plan for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended oradopted orterminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
The following table describes contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended (each a "Rule 10b5-1 Plan")adopted by our executive officers and directors during the three month period ending December 31, 2024:
| Name | Title | Date of Adoption | Duration of Rule 10b5-1 Plan | Aggregate Number of Securities to be Purchased Pursuant to the Rule 10b5-1 Plan | Aggregate Number of Securities to be Sold Pursuant to the Rule 10b5-1 Plan |
|---|---|---|---|---|---|
| Francis Leonard | Executive Vice President, President Novocure Oncology | November 5, 2024 | December 24, 2024 - December 5, 2025 | — | 282,997 |
During the three-month period ending December 31, 2024, none of our executive officers or directors terminated a Rule 10b5-1 trading plan oradopted orterminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.